1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
4basebio PLC

4basebio PLC

4BB.L
4basebio PLCGB flagLondon Stock Exchange
525.00
GBp
- -
- -
81.30MMarket Cap
4basebio PLC
4BB.L
(London Stock Exchange)

Recent

price

525.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
FRC
0.02
0.04
0.03
0.02
0.04
0.07
0.11
Revenue per Share
-0.03
-0.06
-0.26
-0.42
-0.62
-0.94
-1.09
Basic EPS, GAAP
-0.02
-0.11
-0.29
-0.48
-0.57
-0.87
-1.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.26
0.06
-0.2
-0.62
-1.24
-1.9
-2.7
Book Value per Share
-0.19
1.19
0.85
0.41
-0.26
1.75
0.34
Tangible Book Value per Share
12
12
12
12
12
13
16
Basic Weighted Avg Shares
- -
- -
- -
- -
1
1
2
Sales/Revenue/Turnover
-207.92
-134.63
-943.2
-2,115.3
-1,613.83
-1,371.17
-984.29
Operating Margin (%)
- -
- -
- -
- -
1
1
1
Depreciation Expense
- -
-1
-3
-5
-8
-12
-17
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-209.41
-155.63
-957.1
-1,921.64
-1,514.82
-1,321.86
-998.52
Profit Margin (%)
- -
15
9
4
3
34
18
Working Capital
2
1
1
3
10
15
17
LT Debt
-2
15
12
7
- -
26
10
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-1,138.77%
-61.67%
Free Cash Flow
- -
69.72%
40.35%
Net Income, GAAP
- -
111.19%
37.07%
Sales/Revenue/Turnover
- -
41.42%
81.46%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
2

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.62
2024
- -
- -
- -
- -
-0.94
2025
- -
- -
- -
- -
-1.09

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Hvsen Biotechnology Co., Ltd. (300871.SZ)
Protagonist Therapeutics, Inc. (PTGX)
Ocuphire Pharma, Inc. (OCUP)
Minerva Neurosciences, Inc. (NERV)
Phio Pharmaceuticals Corp. (PHIOW)
Anhui Huaheng Biotechnology Co., Ltd. (688639.SS)
Business
4basebio PLC (AIM: 4BB.L), a Cambridge, United Kingdom-based biotechnology company founded in 2008, develops and manufactures synthetic DNA and RNA products alongside non-viral nucleic acid delivery platforms to accelerate advanced therapy medicinal products including gene therapies, mRNA vaccines and therapeutics, viral vectors, genome editing tools, and DNA vaccines; its core offerings encompass GMP-grade opDNA synthetic DNA templates produced via a proprietary enzymatic cell-free process using TruePrime amplification technology, application-specific dsDNA and ssDNA constructs, custom pegRNA and mRNA synthesis services, RUO-grade off-the-shelf mRNA for reporter genes, and the Hermes targeted non-viral delivery platform featuring thermostable nanoparticles for efficient payload delivery surpassing conventional LNPs. The company serves biopharma, academic, and research clients globally with operations centered in the UK, emphasizing superior speed (up to 4x faster than plasmid DNA), purity, scalability, and safety by eliminating bacterial sequences. Recent developments include securing MHRA GMP manufacturing license in April 2025 enabling clinical-grade DNA supply, completing a £40 million strategic equity investment from Elevage Medical Technologies and M&G Investment Management in November 2024, achieving revenue growth to £1.2 million in H1 2025 (nearly 4x YoY) with opDNA powering a tier-1 pharma's FDA IND-approved mRNA vaccine and partnerships like HelixNano, introducing refreshed branding and website in July 2025, participating in a £1.2 million UK-Canada consortium for influenza vaccine development in July 2025, expanding its IP portfolio to 31 patent families, and scaling commercial teams to target late preclinical and IND-stage clients.